JPMorgan Chase & Co. Cuts Holdings in Oaktree Acquisition Corp. III Life Sciences $OACC

Key Points

• JPMorgan Chase cut its position in Oaktree Acquisition Corp. III Life Sciences by 62.5% in Q3, selling 124,959 shares and finishing the quarter with 74,817 shares (~0.33% ownership) worth about $783,000.
• Other institutions added or initiated sizable stakes—Radcliffe Capital (+175.5% to 225,662 shares, ~$2.37M), Berkley W R (+125.2% to 223,645 shares, ~$2.35M), Verition (+6.7% to 161,740 shares, ~$1.69M), while Whitebox and Millennium opened new positions valued at about $2.61M and $4.85M respectively.
• Analyst sentiment is negative with a consensus "Sell" rating (Weiss Ratings reiterated a sell), and the SPAC trades around $10.67 (12‑month range $10.04–$10.74) as it pursues life‑sciences acquisitions.

JPMorgan Chase & Co. cut its position in shares of Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC - Free Report) by 62.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 74,817 shares of the company's stock after selling 124,959 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.33% of Oaktree Acquisition Corp. III Life Sciences worth $783,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Radcliffe Capital Management L.P. boosted its holdings in Oaktree Acquisition Corp. III Life Sciences by 175.5% during the third quarter. Radcliffe Capital Management L.P. now owns 225,662 shares of the company's stock worth $2,372,000 after purchasing an additional 143,749 shares during the last quarter. Berkley W R Corp boosted its holdings in Oaktree Acquisition Corp. III Life Sciences by 125.2% during the third quarter. Berkley W R Corp now owns 223,645 shares of the company's stock worth $2,351,000 after purchasing an additional 124,315 shares during the last quarter. Verition Fund Management LLC boosted its holdings in Oaktree Acquisition Corp. III Life Sciences by 6.7% during the third quarter. Verition Fund Management LLC now owns 161,740 shares of the company's stock worth $1,693,000 after purchasing an additional 10,117 shares during the last quarter. Whitebox Advisors LLC purchased a new position in Oaktree Acquisition Corp. III Life Sciences in the second quarter valued at about $2,612,000. Finally, Millennium Management LLC purchased a new position in Oaktree Acquisition Corp. III Life Sciences in the first quarter valued at about $4,848,000.

Oaktree Acquisition Corp. III Life Sciences Trading Up 0.6%

OACC opened at $10.67 on Friday. Oaktree Acquisition Corp. III Life Sciences has a twelve month low of $10.04 and a twelve month high of $10.74. The company's 50-day moving average price is $10.65 and its two-hundred day moving average price is $10.61.

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC - Get Free Report) last released its earnings results on Thursday, March 26th. The company reported $0.08 earnings per share for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a "sell (d)" rating on shares of Oaktree Acquisition Corp. III Life Sciences in a research note on Thursday, April 2nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of "Sell".

Oaktree Acquisition Corp. III Life Sciences Company Profile

Oaktree Acquisition Corp. III Life Sciences NASDAQ: OACC is a special purpose acquisition company (“SPAC”) formed to pursue merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses in the life sciences sector. Incorporated as a Cayman Islands exempted company, OACC is sponsored by Oaktree Capital Management, a global alternative investment firm with a longstanding track record in credit strategies and private equity.

Want to see what other hedge funds are holding OACC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.